Aventura Private Wealth LLC Takes $834,000 Position in Stryker Corporation $SYK

Aventura Private Wealth LLC bought a new position in shares of Stryker Corporation (NYSE:SYK) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 2,372 shares of the medical technology company’s stock, valued at approximately $834,000.

Other large investors have also added to or reduced their stakes in the company. Norges Bank bought a new position in Stryker during the second quarter worth $1,882,173,000. Alliancebernstein L.P. boosted its holdings in shares of Stryker by 307.6% during the second quarter. Alliancebernstein L.P. now owns 5,596,508 shares of the medical technology company’s stock worth $2,214,146,000 after acquiring an additional 4,223,366 shares during the period. Corient Private Wealth LLC grew its position in shares of Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after purchasing an additional 1,146,998 shares during the last quarter. Strive Asset Management LLC bought a new position in shares of Stryker during the third quarter worth approximately $227,389,000. Finally, Credit Agricole S A bought a new position in shares of Stryker during the third quarter worth approximately $194,045,000. Institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. BTIG Research boosted their price target on Stryker from $410.00 to $412.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Sanford C. Bernstein lifted their target price on Stryker from $450.00 to $465.00 and gave the stock an “outperform” rating in a report on Friday, January 9th. Weiss Ratings restated a “hold (c+)” rating on shares of Stryker in a research note on Monday, December 22nd. Evercore set a $390.00 price target on shares of Stryker in a research report on Monday, January 5th. Finally, Barclays reiterated an “overweight” rating and issued a $469.00 price objective on shares of Stryker in a research note on Monday, February 2nd. Fourteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and an average target price of $427.50.

Stryker Stock Down 1.1%

Shares of Stryker stock opened at $335.96 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. The company has a 50-day moving average of $363.25 and a 200 day moving average of $366.04. Stryker Corporation has a 1 year low of $328.23 and a 1 year high of $404.87. The firm has a market cap of $128.57 billion, a price-to-earnings ratio of 39.99, a PEG ratio of 1.99 and a beta of 0.85.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, topping the consensus estimate of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The company had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.12 billion. During the same quarter in the prior year, the business posted $4.01 EPS. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. Stryker’s dividend payout ratio (DPR) is 41.90%.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 250,000 shares of the company’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares of the company’s stock, valued at $891,814,566.52. This represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.